Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells

Chi,Zuofei; Gao,Hongyu; Liu,Hui; Wu,Bin; Zhang,Bin; Gu,Min; Yang,Wei

doi:10.3892/mmr.2019.10873

Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells

Authors:
- Zuofei Chi
- Hongyu Gao
- Hui Liu
- Bin Wu
- Bin Zhang
- Min Gu
- Wei Yang
View Affiliations

Affiliations: Department of Pediatric Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022, P.R. China, Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022, P.R. China
Published online on: December 10, 2019 https://doi.org/10.3892/mmr.2019.10873
Pages: 936-944

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

T‑cell acute lymphoblastic leukemia (T‑ALL) is a hematopoietic malignancy, which is associated with a poor prognosis. It is difficult to achieve complete remission or long‑term survival with conventional chemotherapy, partly due to decreased apoptosis. However, necroptosis can serve as an alternative pathway to induce cell death. The present study investigated whether the selective histone deacetylase (HDAC) inhibitor chidamide exerted a therapeutic effect on T‑ALL and explored the underlying mechanism. The results revealed that HDAC expression was increased in Jurkat and HUT‑78 cells treated compared with the control cell line (H9), and was accompanied by elevated cellular Fas‑associated death domain‑like interleukin‑1β converting enzyme inhibitory protein long form (c‑FLIPL) levels. Chidamide treatment (2 µmol/l) also induced mitochondrial dysfunction, necroptosis and apoptosis in T‑ALL cells in vitro. Furthermore, necroptosis was increased when apoptosis was blocked in T‑ALL cells. Additionally, chidamide (2 µmol/l) downregulated c‑FLIPL, HDAC1 and HDAC3 expression, and increased receptor‑interacting protein kinase 3 expression and the phosphorylation of mixed lineage kinase domain‑like pseudokinase in Jurkat and HUT‑78 cells. The results obtained in the present study revealed that chidamide may induce necroptosis via regulation of c‑FLIPL expression when apoptosis is inhibited in Jurkat and HUT‑78 cells.

View Figures

View References

1	Beesley AH, Firth MJ, Ford J, Weller RE, Freitas JR, Perera KU and Kees UR: Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer. 100:1926–1936. 2009. View Article : Google Scholar : PubMed/NCBI
2	He MX and He YW: CFLAR/c-FLIPL: A star in the autophagy, apoptosis and necroptosis alliance. Autophagy. 9:791–793. 2013. View Article : Google Scholar : PubMed/NCBI
3	Sachanas S, Levidou G, Angelopoulou MK, Moschogiannis M, Yiakoumis X, Kalpadakis C, Vassilakopoulos TP, Kontopidou F, Tsirkinidis P, Dimitrakopoulou A, et al: Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 55:571–582. 2014. View Article : Google Scholar : PubMed/NCBI
4	Venza I, Visalli M, Oteri R, Teti D and Venza M: Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharmacol. 21:439–446. 2014. View Article : Google Scholar : PubMed/NCBI
5	Zheng Z, Cheng S, Wu W, Wang L, Zhao Y, Shen Y, Janin A and Zhao WL: C-FLIP is involved in tumor progression of Peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors. J Hematol Oncol. 7:882014. View Article : Google Scholar : PubMed/NCBI
6	Su Z, Yang Z, Xu Y, Chen Y and Yu Q: Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 14:482015. View Article : Google Scholar : PubMed/NCBI
7	Deng XX, Li SS and Sun FY: Necrostatin-1 prevents necroptosis in brains after ischemic stroke via inhibition of RIPK1-mediated RIPK3/MLKL signaling. Aging Dis. 10:807–817. 2019. View Article : Google Scholar : PubMed/NCBI
8	Pasparakis M and Vandenabeele P: Necroptosis and its role in inflammation. Nature. 517:311–320. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhang B, Cao K, Liu Z, Shan W, Wen Q and Wang R: Receptor interacting protein kinase 3 promotes cisplatin-induced necroptosis in apoptosis-resistant HepG2/DDP cells. Neoplasma. 2019:180710N4662019.PubMed/NCBI
10	Fu D, Jordan JJ and Samson LD: Human ALKBH7 is required for alkylation and oxidation-induced programmed necrosis. Genes Dev. 27:1089–1100. 2013. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Pietkiewicz S, Schmidt JH and Lavrik IN: Quantification of apoptosis and necroptosis at the single cell level by a combination of imaging flow cytometry with classical Annexin V/propidium iodide staining. J Immunol Methods. 423:99–103. 2015. View Article : Google Scholar : PubMed/NCBI
13	NCCN Clinical Practice Guidelines in Oncology, . Pediatric Acute Lymphoblastic Leukemia. Version1. 2018 March 12;2018.
14	Hu X and Xuan Y: Bypassing cancer drug resistance by activating multiple death pathways-A proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 259:127–137. 2008. View Article : Google Scholar : PubMed/NCBI
15	Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, et al: Inhibition of death receptor signals by cellular FLIP. Nature. 388:190–195. 1997. View Article : Google Scholar : PubMed/NCBI
16	Hsu TS, Mo ST, Hsu PN and Lai MZ: c-FLIP is a target of the E3 ligase deltex1 in gastric cancer. Cell Death Dis. 9:1352018. View Article : Google Scholar : PubMed/NCBI
17	Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD and Kim SH: Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol. 77:1328–1336. 2009. View Article : Google Scholar : PubMed/NCBI
18	Mclornan D, Hay J, Mclaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB and Gilkes A: Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol. 160:188–198. 2013. View Article : Google Scholar : PubMed/NCBI
19	Florean C, Schnekenburger M, Grandjenette C, Dicato M and Diederich M: Epigenomics of leukemia: From mechanisms to therapeutic applications. Epigenomics. 3:581–609. 2011. View Article : Google Scholar : PubMed/NCBI
20	Xiao PF, Tao YF, Hu SY, Cao L, Lu J, Wang J, Feng X, Pan J and Chai YH: mRNA expression profiling of histone modifying enzymes in pediatric acute monoblastic leukemia. Pharmazie. 72:177–186. 2017.PubMed/NCBI
21	Haery L, Mussakhan S, Waxman DJ and Gilmore TD: Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. Leuk Lymphoma. 57:2661–2671. 2016. View Article : Google Scholar : PubMed/NCBI
22	Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE and Andersson BS: Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 9:3908–3921. 2017.PubMed/NCBI
23	Zhou H, Cai Y, Liu D, Li M, Sha Y, Zhang W, Wang K, Gong J, Tang N, Huang A and Xia J: Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21 Waf1/Cip1 and p19 INK4d upregulation in hepatocellular carcinoma. Cell Prolif. 51:e124472018. View Article : Google Scholar : PubMed/NCBI
24	Li S, Wang F, Qu Y, Chen X, Gao M, Yang J, Zhang D, Zhang N, Li W and Liu H: HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells. Oncol Lett. 13:403–409. 2017. View Article : Google Scholar : PubMed/NCBI
25	Ahn MY and Yoon JH: Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. Oncol Rep. 37:540–546. 2017. View Article : Google Scholar : PubMed/NCBI
26	Yoon S and Eom GH: HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 52:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
27	Chan TS, Tse E and Kwong YL: Chidamide in the treatment of peripheral T-cell lymphoma. Onco Targets Ther. 10:347–352. 2017. View Article : Google Scholar : PubMed/NCBI
28	Lu CT, Leong PY, Hou TY, Huang SJ, Hsiao YP and Ko JL: Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction. Phytomedicine. 51:39–47. 2018. View Article : Google Scholar : PubMed/NCBI
29	Yang S, Nan P, Li C, Lin F, Li H, Wang T, Zhou C, Zhang X, Meng X, Qian H, et al: Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. Biomed Pharmacother. 99:608–614. 2018. View Article : Google Scholar : PubMed/NCBI
30	Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA and Yuan J: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 1:112–119. 2005. View Article : Google Scholar : PubMed/NCBI
31	Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, et al: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 41:1006–1010. 2009. View Article : Google Scholar : PubMed/NCBI
32	Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ and Han J: RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 325:332–336. 2009. View Article : Google Scholar : PubMed/NCBI
33	Qiu X, Zhang Y and Han J: RIP3 is an upregulator of aerobic metabolism and the enhanced respiration by necrosomal RIP3 feeds back on necrosome to promote necroptosis. Cell Death Differ. 25:821–824. 2018.PubMed/NCBI
34	Cook WD, Moujalled DM, Ralph TJ, Lock P, Young SN, Murphy JM and Vaux DL: RIPK1-and RIPK3-induced cell death mode is determined by target availability. Cell Death Differ. 21:1600–1612. 2014. View Article : Google Scholar : PubMed/NCBI
35	Xu B, Xu M, Tian Y, Yu Q, Zhao Y, Chen X, Mi P, Cao H, Zhang B, Song G, et al: Matrine induces RIP3-dependent necroptosis in cholangiocarcinoma cells. Cell Death Discov. 3:160962017. View Article : Google Scholar : PubMed/NCBI
36	Kim SK, Kim WJ, Yoon JH, Ji JH, Morgan MJ, Cho H, Kim YC and Kim YS: Upregulated RIP3 Expression Potentiates MLKL phosphorylation-mediated programmed necrosis in toxic epidermal Necrolysis. J Invest Dermatol. 135:2021–2030. 2015. View Article : Google Scholar : PubMed/NCBI
37	Moujalled DM, Cook WD, Murphy JM and Vaux DL: Necroptosis induced by RIPK3 requires MLKL but not Drp1. Cell Death Dis. 5:e10862014. View Article : Google Scholar : PubMed/NCBI